Aclaris Therapeutics Inc (ACRS) Implied Volatility Current

Tracking ACRS implied volatility helps you identify when options premiums on Aclaris Therapeutics Inc are historically cheap or expensive, and where the best trades are hiding. Aclaris Therapeutics Inc implied volatility reflects the market's expectation of future price movement: when ACRS IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Aclaris Therapeutics Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For ACRS, tracking metrics like ACRS IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on ACRS signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis.

In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where ACRS implied volatility sits today versus where it has been. Our scanner ranks Aclaris Therapeutics Inc implied volatility against its historical range, surfaces extremes in ACRS IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Aclaris Therapeutics Inc IV is rich or cheap — measure it, then act on it.